

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

HARA [Human squamous cell lung carcinoma]

RRID:CVCL_2914

Type: Cell Line

Proper Citation

RRID:CVCL_2914

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2914

Proper Citation: RRID:CVCL_2914

Description: Cell line HARA [Human squamous cell lung carcinoma] is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:8287365](#), [PMID:8752176](#), [PMID:12569360](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24002593](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP)., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HARA [Human squamous cell lung carcinoma]

Synonyms: KCC-C1

Cross References: CLO:CLO_0009998, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:714, BioSample:SAMN03472500, BioSample:SAMN10987873, cancercellines:CVCL_2914, Cell_Model_Passport:SIDM00598, Cosmic:1995421, Cosmic:2060530, Cosmic-CLP:1240142, DepMap:ACH-000843, EGA:EGAS00001000978, GDSC:1240142, GEO:GSM827377, GEO:GSM887032, GEO:GSM888102, GEO:GSM1374487, GEO:GSM1669839, IARC_TP53:28383, JCRB:JCRB1080.0, JCRB:NIHS0352.0,

LiGeA:CCLE_673, LINCS_LDP:LCL-1585, PharmacDB:HARA_442_2019, PRIDE:PXD030304, Progenetix:CVCL_2914, Wikidata:Q54881313

ID: CVCL_2914

Record Creation Time: 20220427T220314+0000

Record Last Update: 20260905T180211+0000

Ratings and Alerts

No rating or validation information has been found for HARA [Human squamous cell lung carcinoma].

No alerts have been found for HARA [Human squamous cell lung carcinoma].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yokoyama H, et al. (2026) Glypican-1-targeted antibody-drug conjugate shows therapeutic efficacy in lung squamous cell carcinoma. Lung cancer (Amsterdam, Netherlands), 217, 109431.

Zeng J, et al. (2026) KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma. Cancer research, 86(7), 1622.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Plowman T, et al. (2025) Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. Science immunology, 10(109), eadr1105.

Attig J, et al. (2023) Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin. The Journal of clinical investigation, 133(14).

Meneses KM, et al. (2023) RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion. Cancer research communications, 3(4), 607.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer cell, 41(1), 88.

Kazachenka A, et al. (2023) The transcriptional landscape of endogenous retroelements delineates esophageal adenocarcinoma subtypes. *NAR cancer*, 5(3), zcad040.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.